Abstract
The monoclonal antibody lecanemab reduced brain amyloid levels compared with placebo and slowed decline in cognition and function in patients with early Alzheimer's disease, a Phase 3 study has found. The Food and Drug Administration in January approved lecanemab for the treatment of Alzheimer's disease (see related item in From the FDA section, page 8).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
